Allogeneic mesenchymal stem cells for Crohn’s disease-associated complex perianal fistulas

Wolf S, Stanak M
Record ID 32018000321
English
Authors' objectives: Standard treatments for Crohn’s disease (CD)-associated complex perianal fistulas result in high recurrence rates. We reviewed current evidence on efficacy and safety of allogeneic mesenchymal stem cells (MSCs) as an add-on therapy in refractory patients, compared to placebo therapy, fibrin glue or fistula plugs.
Authors' results and conclusions: Current evidence suggested that MSC-therapies lead to slight improvements of combined remission, though results for quality of life are inconclusive. It remains unclear if MSCs are safer than placebo procedures. The overall body of evidence was rated with very low evidence. RCTs comparing MSCs with therapies other than placebo, as well as long-term evidence, were lacking.
Authors' recomendations: At present, we do not recommend the inclusion of MSCs as an add-on therapy in refractory CD-patients with complex perianal fistulas in the Austrian catalogue of benefits and suggest a reevaluation in 2022.
Authors' methods: Two randomised controlled trials (RCTs), comparing MSCs with placebo, and one single-arm study were evaluated.
Details
Project Status: Completed
Year Published: 2018
URL for published report: http://eprints.aihta.at/1171/1/DSD_111.pdf
URL for additional information: http://eprints.aihta.at/1171/
English language abstract: An English language summary is available
Publication Type: Full HTA
Country: Austria
MeSH Terms
  • Therapeutics
  • Crohn Disease
  • Allogeneic Cells
  • Mesenchymal Stem Cell Transplantation
  • Fistula
Keywords
  • Crohn’s disease
  • complex perianal fistulas
  • mesenchymal stem cells
  • systematic review
Contact
Organisation Name: Ludwig Boltzmann Institute for Health Technology Assessment
Contact Address: Ludwig Boltzmann Institute for fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7/rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99
Contact Name: tarquin.mittermayr@aihta.at
Contact Email: office@aihta.at
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.